6533b81ffe1ef96bd127885b

RESEARCH PRODUCT

Can Be miR-126-3p a Biomarker of Premature Aging? An Ex Vivo and In Vitro Study in Fabry Disease

Anna AielloGiulia AccardiGiuseppina CandoreRiccardo AlessandroRiccardo AlessandroDaniele FrancofonteCarmela ZizzoGiuseppe CammarataGiorgia AdamoGiovanni DuroPaolo ColombaAlessia Lo CurtoRosa PassantinoGiuseppa AugelloMarco ZoraTiziana Di ChiaraCalogero CarusoMaria Assunta CostaSimona Taverna

subject

SenescencePremature agingAdultMalesenescenceAdolescentPopulationsmall extracellular vesiclesUmbilical veinArticleAndrologyExtracellular VesiclesYoung AdultHUVECIn vivosmall extracellular vesicleHuman Umbilical Vein Endothelial CellsmiR-126-3pMedicineHumanseducationlcsh:QH301-705.5Cellular SenescenceAgedAged 80 and overSettore MED/04 - Patologia Generaleeducation.field_of_studySphingolipidsFabry diseasemicroRNAbusiness.industryagingAging PrematureGeneral MedicineMiddle Agedmedicine.diseaseFabry diseaseendothelial cellsMicroRNAslcsh:Biology (General)endothelial cellBiomarker (medicine)NanoparticlesFemaleGlycolipidsbusinessReactive Oxygen SpeciesEx vivoBiomarkers

description

Fabry disease (FD) is a lysosomal storage disorder (LSD) characterized by lysosomal accumulation of glycosphingolipids in a wide variety of cytotypes, including endothelial cells (ECs). FD patients experience a significantly reduced life expectancy compared to the general population

yearjournalcountryeditionlanguage
2021-02-01Cells
10.3390/cells10020356http://dx.doi.org/10.3390/cells10020356